Abstract
Bone was reported as a crucial organ for regulating glucose homeostasis. In this study, we found that Phex mutant mice (PUG), a model of human X-linked hypophosphatemic rickets (XLH), displayed metabolic abnormality in addition to abnormal phosphate homeostasis, skeletal deformity and growth retardation. Glucose tolerance was elevated with enhanced insulin sensitivity in PUG, though circulating insulin level decreased. Interestingly, bone mineral density defects and glucose metabolic abnormality were both rescued by adding phosphorus- and calcium-enriched supplements in daily diet. Serum insulin level, glucose tolerance and insulin sensitivity showed no differences between PUG and wild-type mice with rescued osteocalcin (OCN) following treatment. Our study suggested that OCN is a potential mediator between mineral homeostasis and glucose metabolism. This investigation brings a new perspective on glucose metabolism regulation through skeleton triggered mineral homeostasis and provides new clues in clinical therapeutics of potential metabolic disorders in XLH patients.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Jap TS, Chiu CY, Niu DM, Levine MA. Three novel mutations in the PHEX gene in Chinese subjects with hypophosphatemic rickets extends genotypic variability. Calcif Tissue Int, 2011, 88: 370–377
Tenenhouse HS. X-linked hypophosphataemia: a homologous disorder in humans and mice. Nephrol Dial Transplant, 1999, 14: 333–341
Drezner MK. PHEX gene and hypophosphatemia. Kidney Int, 2000, 57: 9–18
Ichikawa S, Traxler EA, Estwick SA, Curry LR, Johnson ML, Sorenson AH, Imel EA, Econs MJ. Mutational survey of the PHEX gene in patients with X-linked hypophosphatemic rickets. Bone, 2008, 43: 663–666
Baroncelli GI, Bertelloni S, Sodini F, Galli L, Vanacore T, Fiore L, Saggese G. Genetic advances, biochemical and clinical features and critical approach to treatment of patients with X-linked hypophosphatemic rickets. Pediatr Endocrinol Rev, 2004, 1: 361–379
Du L, Desbarats M, Viel J, Glorieux FH, Cawthorn C, Ecarot B. cDNA cloning of the murine Pex gene implicated in X-linked hypophosphatemia and evidence for expression in bone. Genomics, 1996, 36: 22–28
Fukumoto S, Martin TJ. Bone as an endocrine organ. Trends Endocrinol Metab, 2009, 20: 230–236
Vervloet MG, Massy ZA, Brandenburg VM, Mazzaferro S, Cozzolino M, Urena-Torres P, Bover J, Goldsmith D. Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. Lancet Diabetes Endocrinol, 2014, 2: 427–436
Chen X, Tian HM, Pei FX, Yu XJ. Bone functions as a novel endocrine organ in energy metabolism. Chin Med J, 2012, 125: 4117–4121
Garcia-Martin A, Reyes-Garcia R, Avila-Rubio V, Munoz-Torres M. Osteocalcin: a link between bone homeostasis and energy metabolism. Endocrinol Nutr, 2013, 60: 260–263
Pi M, Quarles LD. Novel bone endocrine networks integrating mineral and energy metabolism. Curr Osteop Rep, 2013, 11: 391–399
Yuan B, Takaiwa M, Clemens TL, Feng JQ, Kumar R, Rowe PS, Xie Y, Drezner MK. Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest, 2008, 118: 722–734
Salmon B, Bardet C, Khaddam M, Naji J, Coyac BR, Baroukh B, Letourneur F, Lesieur J, Decup F, Le Denmat D, Nicoletti A, Poliard A, Rowe PS, Huet E, Vital SO, Linglart A, McKee MD, Chaussain C. MEPE-derived ASARM peptide inhibits odontogenic differentiation of dental pulp stem cells and impairs mineralization in tooth models of X-linked hypophosphatemia. PLoS One, 2013, 8: e56749
Rowe PS. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway. Crit Rev Eukaryot Gene Exp, 2012, 22: 61–86
Roetzer KM, Varga F, Zwettler E, Nawrot-Wawrzyniak K, Haller J, Forster E, Klaushofer K. Novel PHEX mutation associated with hypophosphatemic rickets. Nephron Physiol, 2007, 106: 8–12
Cheung M, Roschger P, Klaushofer K, Veilleux LN, Roughley P, Glorieux FH, Rauch F. Cortical and trabecular bone density in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab, 2013, 98: E954–961
Uchihashi K, Nakatani T, Goetz R, Mohammadi M, He X, Razzaque MS. FGF23-induced hypophosphatemia persists in Hyp mice deficient in the WNT coreceptor Lrp6. Contrib Nephrol, 2013, 180: 124–137
Sun X, Zemel MB. 1Alpha,25-dihydroxyvitamin D3 modulation of adipocyte reactive oxygen species production. Obesity (Silver Spring), 2007, 15: 1944–1953
Wong KE, Szeto FL, Zhang W, Ye H, Kong J, Zhang Z, Sun XJ, Li YC. Involvement of the vitamin D receptor in energy metabolism: regulation of uncoupling proteins. Am J Physiol Endocrinol Metab, 2009, 296: E820–828
Wang WL, Welsh J, Tenniswood M. 1,25-Dihydroxyvitamin D3 modulates lipid metabolism in prostate cancer cells through miRNA mediated regulation of PPARA. J Steroid Biochem Mol Biol, 2013, 136: 247–251
Mirza MA, Alsio J, Hammarstedt A, Erben RG, Michaelsson K, Tivesten A, Marsell R, Orwoll E, Karlsson MK, Ljunggren O, Mellstrom D, Lind L, Ohlsson C, Larsson TE. Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol, 2011, 31: 219–227
Muhlbauer RC, Fleisch H. Abnormal renal glucose handling in X-linked hypophosphataemic mice. Clin Sci (Lond), 1991, 80: 71–76
Capparelli AW, Roh D, Dhiman JK, Jo OD, Yanagawa N. Altered proximal tubule glucose metabolism in X-linked hypophosphatemic mice. Endocrinology, 1992, 130: 328–334
Rifas L, Gupta A, Hruska KA, Avioli LV. Altered osteoblast gluconeogenesis in X-linked hypophosphatemic mice is associated with a depressed intracellular pH. Calcif Tissue Int, 1995, 57: 60–63
Feng JQ, Clinkenbeard EL, Yuan B, White KE, Drezner MK. Osteocyte regulation of phosphate homeostasis and bone mineralization underlies the pathophysiology of the heritable disorders of rickets and osteomalacia. Bone, 2013, 54: 213–221
Confavreux CB. Bone: from a reservoir of minerals to a regulator of energy metabolism. Kidney Int Suppl, 2011, 121: S14–19
Addison WN, Masica DL, Gray JJ, McKee MD. Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage. J Bone Miner Res, 2010, 25: 695–705
Jones G. Early life nutrition and bone development in children. Nestle Nutr Workshop Ser Pediatr Program, 2011, 68: 227–233; discussion 233–226
Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G. Endocrine regulation of energy metabolism by the skeleton. Cell, 2007, 130: 456–469
Neve A, Corrado A, Cantatore FP. Osteocalcin: skeletal and extra-skeletal effects. J Cell Physiol, 2013, 228: 1149–1153
Bourne W. The present status of avertin in anaesthesia. Can Med Assoc J, 1932, 27: 515–516
Seitz S, Rendenbach C, Barvencik F, Streichert T, Jeschke A, Schulze J, Amling M, Schinke T. Retinol deprivation partially rescues the skeletal mineralization defects of Phex-deficient Hyp mice. Bone, 2013, 53: 231–238
Xiong X, Qi X, Ge X, Gu P, Zhao J, Zhao Q, Gao X. A novel Phex mutation with defective glycosylation causes hypophosphatemia and rickets in mice. J Biomed Sci, 2008, 15: 47–59
Linglart A, Biosse-Duplan M, Briot K, Chaussain C, Esterle L, Guillaume-Czitrom S, Kamenicky P, Nevoux J, Prie D, Rothenbuhler A, Wicart P, Harvengt P. Therapeutic management of hypopho- sphatemic rickets from infancy to adulthood. Endocr Connect, 2014, 3: R13–30
Quinlan C, Guegan K, Offiah A, Neill RO, Hiorns MP, Ellard S, Bockenhauer D, Hoff WV, Waters AM. Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment. Pediatr Nephrol, 2012, 27: 581–588
Aono Y, Yamazaki Y, Yasutake J, Kawata T, Hasegawa H, Urakawa I, Fujita T, Wada M, Yamashita T, Fukumoto S, Shimada T. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res, 2009, 24: 1879–1888
Civitelli R, Ziambaras K. Calcium and phosphate homeostasis: concerted interplay of new regulators. J Endocrinol Invest, 2011, 34: 3–7
Begot L, Collombet JM, Renault S, Butigieg X, Andre C, Zerath E, Holy X. Effects of high-phosphorus and/or low-calcium diets on bone tissue in trained male rats. Med Sci Sports Exerc, 2011, 43: 54–63
Aoki A, Muneyuki T, Yoshida M, Munakata H, Ishikawa SE, Sugawara H, Kawakami M, Kakei M. Circulating osteocalcin is increased in early-stage diabetes. Diabetes Res Clin Pract, 2011, 92: 181–186
Li X, Srivastava AK, Gu W, Masinde G, Mohan S, Baylink DJ. Opposing changes in osteocalcin levels in bone vs serum during the acquisition of peak bone density in C3H/HeJ and C57BL/6J mice. Calcif Tissue Int, 2002, 71: 416–420
Garcia-Caraballo SC, Comhair TM, Verheyen F, Gaemers I, Schaap FG, Houten SM, Hakvoort TB, Dejong CH, Lamers WH, Koehler SE. Prevention and reversal of hepatic steatosis with a high-protein diet in mice. Biochim Biophys Acta, 2013, 1832: 685–695
Xie W, Mechin MC, Dubois SG, Lajeunesse D, van de Werve G. Up-regulation of liver glucose-6-phosphatase in X-linked hypopho-sphatemic mice. Horm Metab Res, 2002, 34: 288–292
Berglund ED, Li CY, Ayala JE, McGuinness OP, Wasserman DH. Regulation of endogenous glucose production in glucose transporter 4 over-expressing mice. PLoS One, 2012, 7: e52355
Troy S, Soty M, Ribeiro L, Laval L, Migrenne S, Fioramonti X, Pillot B, Fauveau V, Aubert R, Viollet B, Foretz M, Leclerc J, Duchampt A, Zitoun C, Thorens B, Magnan C, Mithieux G, Andreelli F. Intestinal gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice. Cell metabolism, 2008, 8: 201–211
Hill HS, Grams J, Walton RG, Liu J, Moellering DR, Garvey WT. Carboxylated and uncarboxylated forms of osteocalcin directly modulate the glucose transport system and inflammation in adipocytes. Horm Metab Res, 2014, 46: 341–347
Labouesse MA, Gertz ER, Piccolo BD, Souza EC, Schuster GU, Witbracht MG, Woodhouse LR, Adams SH, Keim NL, Van Loan MD. Associations among endocrine, inflammatory, and bone markers, body composition and weight loss induced bone loss. Bone, 2014, 64C: 138–146
Wei J, Ferron M, Clarke CJ, Hannun YA, Jiang H, Blaner WS, Karsenty G. Bone-specific insulin resistance disrupts whole-body glucose homeostasis via decreased osteocalcin activation. J Clin Invest, 2014, 124: 1–13
Zhai YK, Pan YL, Niu YB, Li CR, Wu XL, Fan WT, Lu TL, Mei QB, Xian CJ. The importance of the prenyl group in the activities of osthole in enhancing bone formation and inhibiting bone resorption in vitro. Int J Endocrinol, 2014, 2014: 921954
Petrova NL, Dew TK, Musto RL, Sherwood RA, Bates M, Moniz CF, Edmonds ME. Inflammatory and bone turnover markers in a cross-sectional and prospective study of acute Charcot osteoarthropathy. Diabetic Med, 2015, 32: 267–273
Sheng L, Cao W, Cha B, Chen Z, Wang F, Liu J. Serum osteocalcin level and its association with carotid atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol, 2013, 12: 22
Yamaguchi T, Sugimoto T. Bone metabolism and fracture risk in type 2 diabetes mellitus. Bonekey Rep, 2012, 1: 36
Gao X, Ma W, Dong H, Yong Z, Su R. Establishing a rapid animal model of osteoporosis with ovariectomy plus low calcium diet in rats. Int J Clin Exp Pathol, 2014, 7: 5123–5128
Cawley NX, Yanik T, Woronowicz A, Chang W, Marini JC, Loh YP. Obese carboxypeptidase E knockout mice exhibit multiple defects in peptide hormone processing contributing to low bone mineral density. Am J Physiol Endocrinol Metab, 2010, 299: E189–197
Buday B, Pach FP, Literati-Nagy B, Vitai M, Vecsei Z, Koranyi L. Serum osteocalcin is associated with improved metabolic state via adiponectin in females versus testosterone in males. Gender specific nature of the bone-energy homeostasis axis. Bone, 2013, 57: 98–104
Mizokami A, Yasutake Y, Gao J, Matsuda M, Takahashi I, Takeuchi H, Hirata M. Osteocalcin induces release of glucagon-like peptide-1 and thereby stimulates insulin secretion in mice. PLoS One, 2013, 8: e57375
Tsuji H, Cawthorn C, Ecarot B. Abnormal modulation of serum osteocalcin by dietary phosphate and 1,25-dihydroxyvitamin D3 in the hypophosphatemic mouse. J Bone Miner Res, 1996, 11: 1234–1240
Motyl KJ, Rosen CJ. Understanding leptin-dependent regulation of skeletal homeostasis. Biochimie, 2012, 94: 2089–2096
Cirmanova V, Bayer M, Starka L, Zajickova K. The effect of leptin on bone: an evolving concept of action. Physiol Res, 2008, 57: S143–151
Karsenty G. Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab, 2006, 4: 341–348
Pogoda P, Egermann M, Schnell JC, Priemel M, Schilling AF, Alini M, Schinke T, Rueger JM, Schneider E, Clarke I, Amling M. Leptin inhibits bone formation not only in rodents, but also in sheep. J Bone Miner Res, 2006, 21: 1591–1599
Amelio PD, Panico A, Spertino E, Isaia GC. Energy metabolism and the skeleton: reciprocal interplay. World J Orthop, 2012, 3: 190–198
Garcia-Martin A, Reyes-Garcia R, Avila-Rubio V, Munoz-Torres M. Osteocalcin: a link between bone homeostasis and energy metabolism. Endocrinol Nutr, 2013, 60: 260–263
Rochefort GY, Rocher E, Aveline PC, Garnero P, Bab I, Chappard C, Jaffre C, Benhamou CL. Osteocalcin-insulin relationship in obese children: a role for the skeleton in energy metabolism. Clin Endocrinol (Oxf), 2011, 75: 265–270
Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, Smith E, Bonadio J, Goldstein S, Gundberg C, Bradley A, Karsenty G. Increased bone formation in osteocalcin-deficient mice. Nature, 1996, 382: 448–452
Gower BA, Pollock NK, Casazza K, Clemens TL, Goree LL, Granger WM. Associations of total and undercarboxylated osteocalcin with peripheral and hepatic insulin sensitivity and beta-cell function in overweight adults. J Clin Endocrinol Metab, 2013, 98: E1173–1180
Rui X, Xu B, Su J, Pan C, Zhan C, Su B, Li H, Wang J, Sheng H, Qu S. Differential pattern for regulating insulin secretion, insulin resistance, and lipid metabolism by osteocalcin in male and female T2DM patients. Med Sci Monit, 2014, 20: 711–719
Lin YY, Chen CY, Chuang TY, Lin Y, Liu HY, Mersmann HJ, Wu SC, Ding ST. Adiponectin receptor 1 regulates bone formation and osteoblast differentiation by GSK-3beta/beta-Catenin signaling in mice. Bone, 2014, 64C: 147–154
Confavreux CB, Levine RL, Karsenty G. A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms. Mol Cell Endocrinol, 2009, 310: 21–29
Motyl KJ, McCabe LR, Schwartz AV. Bone and glucose metabolism: a two-way street. Arch Biochem Biophys, 2010, 503: 2–10
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at link.springer.com
Electronic supplementary material
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Zou, J., Xiong, X., Lai, B. et al. Glucose metabolic abnormality is associated with defective mineral homeostasis in skeletal disorder mouse model. Sci. China Life Sci. 58, 359–367 (2015). https://doi.org/10.1007/s11427-015-4827-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-015-4827-2